

(C) EXCEPT AS PROVIDED BY REGULATION, AN AUTHORIZED RECIPIENT WHO RECEIVES PRESCRIPTION MONITORING DATA FROM THE PROGRAM MAY NOT DISCLOSE THE DATA.

(D) THE PROGRAM MAY DISCLOSE PRESCRIPTION MONITORING DATA AFTER REDACTION OF ALL INFORMATION THAT COULD IDENTIFY A PATIENT, PRESCRIBER, DISPENSER, OR OTHER INDIVIDUAL.

21-2A-07.

(A) THE DEPARTMENT AND ITS AGENTS AND EMPLOYEES ARE NOT SUBJECT TO LIABILITY ARISING FROM:

(1) THE INACCURACY OF ANY INFORMATION SUBMITTED TO THE PROGRAM IN ACCORDANCE WITH THIS SUBTITLE; AND

(2) THE UNAUTHORIZED USE OR DISCLOSURE OF PRESCRIPTION MONITORING DATA PROVIDED TO AN AUTHORIZED RECIPIENT.

(B) AN AUTHORIZED RECIPIENT, ACTING IN GOOD FAITH, IS NOT SUBJECT TO LIABILITY ARISING SOLELY FROM:

(1) REQUESTING OR RECEIVING, OR FAILING TO REQUEST OR RECEIVE, PRESCRIPTION MONITORING DATA FROM THE PROGRAM; OR

(2) ACTING, OR FAILING TO ACT, ON THE BASIS OF PRESCRIPTION MONITORING DATA PROVIDED BY THE PROGRAM FAILURE TO TAKE ACTION ON THE BASIS OF PRESCRIPTION MONITORING DATA PROVIDED BY THE PROGRAM.

21-2A-08.

(A) THE PROGRAM, IN CONSULTATION WITH THE BOARD, SHALL DEVELOP AND IMPLEMENT, OR CONTRACT WITH A VENDOR TO DEVELOP AND IMPLEMENT, EDUCATION AND TRAINING COURSES RELATING TO THE PROGRAM.

(B) THE COURSES REQUIRED UNDER SUBSECTION (A) OF THIS SECTION MAY RELATE TO:

(1) THE TRANSMISSION, ACCESS, AND USE OF PRESCRIPTION MONITORING DATA;

(2) ISSUES ARISING IN PRESCRIBING AND DISPENSING MONITORED PRESCRIPTION DRUGS; ~~AND~~

(3) ISSUES CONCERNING IDENTIFYING AND TREATING SUBSTANCE ABUSE AND ADDICTION; ~~AND~~

(4) THE ROLE OF MONITORED PRESCRIPTION DRUGS IN THE MANAGEMENT OF PAIN, INCLUDING THE DISTINCTION BETWEEN ADDICTION AND PHYSICAL DEPENDENCE.